Stay updated on Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial

Sign up to get notified when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:53:22.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the comparison of cancer risk between patients with type 2 diabetes exposed to dapagliflozin and those exposed to other antidiabetic treatments, specifically focusing on the incidence of breast cancer and bladder cancer among different patient cohorts.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:32.000Z thumbnail image
  7. Check
    17 days ago
    Change Detected
    Summary
    The value 27 (Estimated) has recently changed to 28. This change represents an update in the estimated number of participants in a study comparing the risk of cancer between patients with type 2 diabetes exposed to dapagliflozin and those exposed to other antidiabetic treatments.
    Difference
    0.3%
    Check dated 2024-05-30T09:36:47.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Summary
    The value 04 05 04 04 04 05 04 has recently changed to 05 27 05 24 (Estimated) 05 27 05. This change likely represents an update or revision in the data related to the comparison of cancer incidence among patients with type 2 diabetes exposed to dapagliflozin and other antidiabetic treatments in a multinational cohort database study.
    Difference
    1.0%
    Check dated 2024-05-29T07:56:28.000Z thumbnail image
  9. Check
    24 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide a detailed description of eligibility criteria for the study, including specific inclusion and exclusion criteria for patients newly prescribed dapagliflozin or other antidiabetic drugs. Previously, this section had no information provided.
    Difference
    15%
    Check dated 2024-05-22T21:36:49.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:21:21.000Z thumbnail image

Stay in the know with updates to Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.